Meeting
2018 Genitourinary Cancers Symposium
Treatment and clinical outcomes of very elderly (≥ 80 yrs) metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-institution retrospective analysis.
Authors
Orazio Caffo
Santa Chiara Hospital, Trento, Italy
Orazio Caffo , Stefania Kinspergher , Francesca Maines , Sveva Macrini , Antonello Veccia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 327)
DOI
10.1200/JCO.2018.36.6_suppl.327
Abstract #
327
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
First Author: Orazio Caffo
Poster
2020 Genitourinary Cancers Symposium
Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Celestia S. Higano
Poster
2018 ASCO Annual Meeting
Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).
First Author: Orazio Caffo
Poster
2018 Genitourinary Cancers Symposium
The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience.
First Author: Darren M.C. Poon